Biomed Central Ltd

SHERPA: Unknown

People

  1. Segal
    Segal
  2. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (6)
  2. Gastrointestinal Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Center for Hematologic Malignancies (1)
  5. Hematologic Malignancies, Division of (1)
  6. Lymphoma (1)
Search Within
  1. "Neil Segal"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Department of Medicine (6)
  2. Gastrointestinal Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Center for Hematologic Malignancies (1)
  5. Hematologic Malignancies, Division of (1)
  6. Lymphoma (1)
People
  1. Neil Segal (6)
  2. Andrew Zelenetz (1)
Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2020 (1)
  4. 2016 (3)
Publications
  1. Journal for ImmunoTherapy of Cancer (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
    Journal Article

    Khushalani, N. I.; Ott, P. A.; Ferris, R. L.; Cascone, T.; Schadendorf, D.; Le, D. T.; Sharma, M. R.; Barlesi, F.; Sharfman, W.; Luke, J. J.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results
    Meeting Abstract

    Johnson, M.; Lakhani, N.; Girda, E.; Olszanski, A.; Fong, L.; Han, H.; Casey, K.; Li, S.; Visich, J.; Skokos, D.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase IB/II open-label, randomized evaluation of atezolizumab (atezo) plus selicrelumab (seli) plus gemcitabine plus nab-paclitaxel (gem plus nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
    Meeting Abstract

    Manji, G.; Bahary, N.; Chung, V.; Dalenc, F.; Ducreux, M.; Gomez-Roca, C.; Im, S. A.; Kortmansky, J.; Lacy, J.; Segal, N.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
    Meeting Abstract

    Leidner, R.; Kang, H.; Haddad, R.; Segal, N. H.; Wirth, L. J.; Ferris, R. L.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T. F.; Sharfman, W.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save